Entries Are Sought for Kushner Writing Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

BETHESDA, Md--The American Medical Writers Association is seeking applications for the 1996 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer.

BETHESDA, Md--The American Medical Writers Association is seekingapplications for the 1996 Rose Kushner Awards for Writing Achievementin the Field of Breast Cancer.

Categories include articles (newspapers and magazines, or scientificjournals), books (medical and lay), brochures and monographs,and scripts for video, film, or radio (medical and lay audi-ences).The winning entry in each category is awarded $1,000, providedthrough a grant from Zeneca Pharmaceuticals.

Entries must be received by May 10, 1996. For information, writeto the Rose Kushner Award Committee, American Medical WritersAssociation, 9650 Rockville Pike, Bethesda, MD 20814-3998. Phone301-493-0003 or fax 301-493-6384.

Articles in this issue
Earlier Unrelated BMT Is Effective in CML Subgroup
Taxol/Cisplatin Extends Survival in Advanced Ovarian Ca
Prostate Cancer Patients Face a Host of Psychosocial Issues
NSABP to Study Docetaxel in Operable Breast Cancer
Panel Recommends Approval of Talc for Malignant Pleural Effusions
ODAC Recommends Approval of Verluma for Staging of SCLC
Minorities Lack Internet Access to Cancer Research Data
Fludarabine Produces CRs as First-Line CLL Therapy
M.D. Anderson's C. Stratton Hill Receives Award From American Cancer Society
Managed Care: The View From Salick Managed Care
Selling 'High Risk' Part of an Oncology Practice Can Increase Financial Stability
Entries Are Sought for Kushner Writing Award
Docetaxel Effective as First-Line Breast Cancer Therapy
Roswell Park Institute Establishes Hepatic Cryosurgery Center
High-Dose RAIT May Improve Prognosis in Relapsed NHL Patients
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article